Mode of action of Ipomoea batatas (Caiapo) in type 2 diabetic patients
Mode of action of Ipomoea batatas (Caiapo) in type 2 diabetic patients
复制标题
DOI：
10.1016/s0026-0495(03)00073-8
复制
发表时间：
2003-07-01
影响因子：
9.8
通讯作者：
Pacini, G
中科院分区：
文献类型：
--
作者：
Ludvik, B;Waldhäusl, W;Pacini, G
我们之前已经报道过白皮甘薯提取物Caiapo对2型糖尿病患者的空腹血糖、总胆固醇和低密度脂蛋白(LDL)胆固醇的有益影响。本研究旨在描述在这些2型受试者服用Caiapo后代谢控制改善的潜在机制。18例男性患者(年龄58+/-8岁，体重指数=27.7+/-2.7 kg/m(2)，平均+/-扫描电子显微镜)被随机分为3组：安慰剂组、小剂量Caiapo 2g/d组和大剂量4g/d组。在治疗前和治疗6周后分别进行静脉葡萄糖耐量试验(FSIGT)和口服葡萄糖耐量试验(OGTT)，获得与糖耐量、葡萄糖消失和胰岛素分泌相关的参数。在大剂量Caiapo治疗后，胰岛素敏感性显著改善，OGTT(从308+/-13 mg/min/m(2)到334+/-10，P=.048)和FSIGT(从1.21+/-0.32 10(4)min(-1)/(MU/mL)到1.73+/-0.40，P=.021)。小剂量胰岛素敏感性的改善仅见于FSIGT(从2.02+/-0.70 10(-1)min(-1)/(muu/mL)到2.76+/-0.89，P<；0.05)。葡萄糖的有效性没有改变。虽然在安慰剂组和低剂量组中没有观察到糖耐量的变化，但高剂量组的糖耐量从0.85+/-0.13%min(-1)增加到1.46+/-0.13(P<；02)。与胰岛素动力学相关的任何参数均未见显著变化：胰岛素分泌(来自C-肽)、分布、清除和肝脏提取在治疗后基本保持不变。总而言之，每天服用4g营养品的Caiapo短期治疗可以在不影响体重、葡萄糖有效性或胰岛素动力学的情况下，通过降低胰岛素抵抗来持续改善2型糖尿病患者的代谢控制。未观察到与治疗有关的副作用。因此，这些结果表明，Caiapo可能在2型糖尿病的治疗中发挥作用。(C)2003 Elsevier Inc.保留所有权利。
We have previously reported the beneficial effects of Caiapo, the extract of white-skinned sweet potato (ipomoea batatas), on fasting plasma glucose, as well as on total and low-density lipoprotein (LDL) cholesterol in type 2 diabetic patients. The present study aimed to describe the underlying mechanism responsible for the improvement in metabolic control following administration of Caiapo in those type 2 subjects. A total of 18 male patients (age = 58 +/- 8 years, body mass index [BMI] = 27.7 +/- 2.7 kg/m(2), mean +/- SEM) treated only by diet were randomized into 3 groups (placebo, low-dose Caiapo, 2 g/d, and high-dose, 4 g/d). Parameters related to glucose tolerance, glucose disappearance, and insulin secretion were obtained by performing both frequently sampled intravenous glucose tolerance test (FSIGT) and oral glucose tolerance test (OGTT) before and after 6 weeks of treatment with Caiapo. Following treatment with high dose Caiapo, insulin sensitivity significantly ameliorated when assessed both with OGTT (from 308 +/- 13 mg/min/m(2) to 334 +/- 10, P = .048) and FSIGT (from 1.21 +/- 0.32 10(4) min(-1)/(muU/mL) to 1.73 +/- 0.40, P =.021). Improvement of insulin sensitivity with the low dose was observed only with the FSIGT (from 2.02 +/- 0.70 10(4) min(-1)/(muU/mL) to 2.76 +/- 0.89, P < .05). Glucose effectiveness did not change. While no changes in glucose tolerance were observed in the placebo and low-dose groups, it increased from 0.85 +/- 0.13 %min(-1) to 1.46 +/- 0.13 (P < .02) in patients on high dose. No significant changes were seen in any of the parameters related to insulin dynamics: insulin secretion (from C-peptide), distribution, clearance, and hepatic extraction remained virtually the same after the treatment. In conclusion, short-term treatment with 4 g/d of the nutraceutical Caiapo consistently improved metabolic control in type 2 diabetic patients by decreasing insulin resistance without affecting body weight, glucose effectiveness, or insulin dynamics. No side effects related to the treatment were observed. Thus these results indicate that Caiapo could potentially play a role in the treatment of type 2 diabetes. (C) 2003 Elsevier Inc. All rights reserved.